Compounded Semaglutide: The 2026 Complete Guide

Compounded semaglutide is the same active ingredient found in Wegovy and Ozempic, prepared by a state-licensed compounding pharmacy based on a prescription written by a licensed physician for an individual patient. The active pharmaceutical ingredient is FDA-registered. The finished compounded preparation is not FDA-approved as a final product, which is the same regulatory status that applies to all properly compounded medications under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Compounded semaglutide typically costs $149 to $399 per month through US telehealth providers in 2026. At Majesta Health, sublingual semaglutide (Express) starts at $149 your first month and $199 per month after, and the standard injection (Essential) is $179 your first month and $299 per month after. The brand-name equivalent Wegovy retails for about $1,349 per month without insurance. Pricing typically includes the physician consultation, the medication, and shipping. A $20 medical consultation fee may apply, collected on a pass-through basis to the prescribing provider.

Compounded semaglutide prepared by a properly licensed and inspected compounding pharmacy uses FDA-registered active pharmaceutical ingredient and follows United States Pharmacopeia standards (USP 795, 797, 800 as applicable). Safety depends on three things: the pharmacy's licensure and inspection record, the prescribing physician's evaluation of your medical history, and your honest reporting of conditions and medications. Side effects are similar to brand-name semaglutide and include nausea, decreased appetite, fatigue, and gastrointestinal discomfort. Always disclose pregnancy plans, personal or family history of medullary thyroid cancer or MEN 2, pancreatitis, and any GLP-1 medications you have taken in the past.

No compounded medication is FDA-approved as a final product. The active pharmaceutical ingredient used in compounded semaglutide is FDA-registered. The brand-name products that contain semaglutide (Wegovy, Ozempic, Rybelsus) are FDA-approved products manufactured by Novo Nordisk. Properly compounded preparations are produced legally under Section 503A of the Federal Food, Drug, and Cosmetic Act when prepared for an individual patient based on a prescription.

Both contain semaglutide as the active ingredient. Wegovy is a brand-name FDA-approved injectable. Compounded semaglutide is prepared by a state-licensed compounding pharmacy under a physician prescription. The clinical mechanism is identical because both deliver the same active ingredient. The most common practical differences for patients are cost (compounded options typically range $149 to $399 per month versus about $1,349 per month for Wegovy), formulation choice (compounded options include sublingual troches in addition to standard injections), and access (compounded options have generally avoided the recurring brand-name supply shortages of 2022 to 2024).

Through licensed telehealth platforms, the typical flow is: complete an online medical assessment, consent to telehealth services, have your file reviewed by a US-licensed physician in your state, fill a prescription at a partner compounding pharmacy, and receive monthly shipments to your door. At Majesta Health, the assessment takes about two minutes and you only proceed if your file qualifies you for care.

Most patients begin noticing appetite reduction within the first two to four weeks of starting treatment. Meaningful weight changes typically appear by month three and continue through months six to twelve as the maintenance dose is reached. Published clinical trials of brand-name semaglutide (STEP 1, NEJM 2021) report an average 14.9 percent weight loss at 68 weeks on the highest dose. Individual results vary based on dose, adherence, diet, activity level, and other medical factors.

The standard semaglutide titration starts low and increases gradually to reduce side effects. A common schedule is 0.25 mg per week for month one, 0.5 mg per week for month two, 1.0 mg per week for month three, and 1.7 to 2.4 mg per week thereafter as tolerated. The prescribing physician adjusts the schedule based on your response, side effects, and goals. Do not change your own dose without medical guidance.

Semaglutide is not appropriate for people with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN 2), known severe hypersensitivity to semaglutide, active pancreatitis, type 1 diabetes, current pregnancy or active attempts to conceive, or breastfeeding. People with a history of severe gastrointestinal disease, diabetic retinopathy, or moderate to severe kidney impairment require careful physician evaluation before starting. Always disclose your full medical and medication history during the assessment.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite. These tend to be strongest during dose escalation and improve over weeks. Less common but more serious side effects include pancreatitis, gallbladder problems, severe hypoglycemia (especially in people also taking insulin or sulfonylureas), kidney injury from dehydration, allergic reactions, and changes in diabetic retinopathy. Contact your provider for symptoms that do not improve or are severe.

Stopping any GLP-1 medication abruptly often leads to appetite return and partial weight regain. The clinical literature (STEP 4 extension, JAMA 2021) reports that patients who discontinued semaglutide regained roughly two-thirds of the weight they had lost within one year. A licensed physician can help you build a maintenance plan, which may include reduced dosing, monitored discontinuation, lifestyle support, or transition to a long-term plan based on your goals.

Compounded medications are generally paid out of pocket and not covered by commercial insurance plans, including most plans that cover brand-name Wegovy with prior authorization. HSA and FSA accounts can usually be used for the medical consultation portion when prescribed by a licensed physician for a covered condition. Confirm with your plan administrator.

Injectable semaglutide is administered subcutaneously once per week and is the dosing form used in all major clinical trials. Sublingual semaglutide is a compounded oral troche that dissolves under the tongue, typically taken daily on an empty stomach. Some patients prefer sublingual because it avoids weekly self-injection. Bioavailability profiles differ between the two routes; your prescribing physician will recommend the formulation that fits your medical history, preferences, and goals.

Combining GLP-1 medications with other weight loss drugs, supplements, or other GLP-1 medications is not appropriate without explicit physician guidance because of overlapping mechanisms and increased risk of low blood sugar, dehydration, and gastrointestinal side effects. Disclose every medication and supplement you take during your assessment.

Injectable compounded semaglutide ships in temperature-controlled packaging and is typically stored refrigerated between 36 and 46 degrees Fahrenheit. Sublingual troches are typically stored at controlled room temperature in the original packaging away from light and humidity. Follow the storage instructions on the pharmacy label, which take precedence over general guidance.

Look for these signals: a named US-licensed physician network, a named partner compounding pharmacy that holds LegitScript Healthcare Merchant Certification and NABP accreditation, transparent pricing and disclosure language, a written telehealth informed consent, clear medical assessment with state restriction enforcement, no specific weight loss guarantees, no fake testimonials, and a real physical business address. Avoid providers that promise specific weight loss, ship without a physician evaluation, or advertise prices that look impossibly low.